Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Locate in Scotland, Scottish Trade International Move to New Office
February 19, 2001
- Average Bungyo Rate for All Programs Exceeds 40% for First Time
February 19, 2001
- Korosho Denies Need for Further Deregulation
February 19, 2001
- Sumitomo Revises Sales for 2002 Upward to \150 Billion: President Yokotsuka
February 19, 2001
- FPMAJ Drafts GL for Distinctive Labeling of Paper, Plastic Packages
February 19, 2001
- J&J Pushes Sales of Tylenol Series
February 19, 2001
- Fujisawa Aims at Top Share in Market for Psychotropics
February 19, 2001
- Guide to Prepare NDA Dossiers According to CTD Published
February 19, 2001
- Rohto to Introduce Sliming Supplement from Italy
February 19, 2001
- Santen Licenses in Anti-APO-1 Antibody from Centocor
February 19, 2001
- REGULATORY NEWS IN BRIEF -1-
February 19, 2001
- DyDo to Aggressively Expand Drugstore Business
February 19, 2001
- JT to Withdraw from OTC Business
February 19, 2001
- REGULATORY NEWS IN BRIEF -2-
February 19, 2001
- PAL Violations Found in 96 Pharmacies in 3 Years in Osaka
February 19, 2001
- Industry FTC to Ban Financial Aid for Hospitals' Social Events
February 19, 2001
- Hospitals' Income per Inpatient Down since April 2000: Survey
February 19, 2001
- Households Spent \10,865 Per Month for Healthcare in 2000
February 19, 2001
- Sales of Kampo Medicines Outdo Forecasts: Tsumura
February 19, 2001
- Number of Patients Continues to Decrease at Clinics, Dental Offices: Hodanren Survey
February 19, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…